Iranian Journal of Neurology 2018. 17(2):58-63.

The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder
Roshanak Mehdipour-Dastjerdi, Fereshteh Ashtari, Vahid Shaygannejad, Marjan Mansourian, Ali Safaei


Background: Neuromyelitis optica spectrum disease (NMOSD) is a chronic inflammatory demyelinating disorder that involves central nervous system (CNS) with high affinity for involvement of optic nerve and spinal cord. In current study, due to high prevalence of NMOSD in Isfahan, Iran, we have aimed to assess brain and spine magnetic resonance imaging (MRI) of patients with NMOSD.

Methods: This cross-sectional study was performed on 62 patients with diagnosis of NMOSD, who referred to MS clinic of Kashani hospital, Isfahan City, during 2015-17. Patients' age, age of onset, primary brain and spine MRI findings, and expanded disability status scale (EDSS) were recorded in check list. Patients underwent new brain and spine MRI. Data were analyzed with SPSS software. Descriptive data were reported by mean ± standard deviation (SD).

Results: 62 known cases of NMOSD including
9 (14.5%) men and 53 (85.5%) women with mean age of 34.32 ± 10.26 years, mean age of onset of
28.03 ± 12.09 years, and mean EDSS of 2.63 ± 1.55 were assessed. 33.9% of patients were anti-neuromyelitis optica (NMO) antibody seropositive. Longitudinal extensive transverse myelitis (LETM) and segmental spinal lesions were found in 66.1% and 29.0% of patients, respectively. Diagnostic NMO brain lesions and posterior periventricular lesions were seen in 38.7% and 67.7% of patients, respectively. Two patients had tumefactive lesions.

Conclusion: In current study, we found high rate of posterior periventricular lesions in brain MRI and segmental lesions in spine MRI of both anti-NMO antibody seropositive and seronegative patients. As these lesions are not in NMOSD diagnosis criteria, more considerations are recommended. In addition, tumefactive lesions in patients with NMOSD were an exciting finding of this study that should be discussed about more.


Devic Disease; Neuromyelitis Optica; Magnetic Resonance Imaging; Demyelinating Disease; Cervical Spine

Full Text:



Eshaghi A, Riyahi-Alam S, Saeedi R, Roostaei T, Nazeri A, Aghsaei A, et al. Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis. Neuroimage Clin 2015; 7: 306-14.

Liao MF, Chang KH, Lyu RK, Huang CC, Chang HS, Wu YR, et al. Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. BMC Neurol 2014; 14: 218.

Barhate KS, Ganeshan M, Singhal BS. A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol 2014; 17(1): 77-81.

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261(1): 1-16.

Niino M, Uesugi H, Takahashi T, Fukazawa T, Minami N, Tashiro J, et al. Recurrent brainstem lesions mimicking infarctions in an elderly patient with neuromyelitis optica spectrum disorder. Intern Med 2012; 51(7): 809-12.

Seok JM, Cho HJ, Ahn SW, Cho EB, Park MS, Joo IS, et al. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. Mult Scler 2017; 23(13): 1748-56.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, et al. Revised diagnostic criteria for neuromyelitis optica spectrum disorders (S63.001). Neurology 2014; 82(10 Suppl): S63.001.

Matthews L, Marasco R, Jenkinson M, Kuker W, Luppe S, Leite MI, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 2013; 80(14): 1330-7.

Jurynczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, et al. Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. J Neurol 2016; 263(1): 140-9.

Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gomez JA, et al. Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications. Neurology 2011; 76(14): 1229-37.

Sinnecker T, Dorr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology 2012; 79(7): 708-14.

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85(2): 177-89.

Ashtari F, Safaei A, Shaygannejad V, Najafi MA, Vesal S. Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. J Res Med Sci 2017; 22: 41.

Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015; 21(7): 845-53.

Dale GH, Svendsen KB, Gjelstrup MC, Christensen T, Houen G, Nielsen E, et al. Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. Acta Neurol Scand 2018.

Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76(18): 1589-95.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106-12.

Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T. The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica. Brain Pathol 2014; 24(1): 83-97.

Kessler RA, Mealy MA, Jimenez-Arango JA, Quan C, Paul F, Lopez R, et al. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Mult Scler Relat Disord 2017; 17: 198-201.

Bichuetti DB, Rivero RL, Oliveira DM, Souza NA, Abdala N, Oliveira EM, et al. Neuromyelitis optica: Brain abnormalities in a Brazilian cohort. Arq Neuropsiquiatr 2008; 66(1): 1-4.

Marignier R, Bernard-Valnet R, Giraudon P, Collongues N, Papeix C, Zephir H, et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80(24): 2194-200.

Ikeda K, Ito H, Hidaka T, Takazawa T, Sekine T, Yoshii Y, et al. Repeated non-enhancing tumefactive lesions in a patient with a neuromyelitis optica spectrum disorder. Intern Med 2011; 50(9): 1061-4.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.